Safety Analysis Reveals No Increased Neuropsychiatric Events with CFTR Modulators
A comprehensive safety study shows CFTR modulators do not elevate neuropsychiatric risks among cystic fibrosis patients.
No significant rise in neuropsychiatric events linked to CFTR modulators.
Analysis covered over 250,000 patient-years and included multiple treatment regimens.
Findings suggest a need for further investigation into rare effects in individual patients.
A recent extensive safety analysis has determined that CFTR modulators do not lead to an increased incidence of neuropsychiatric events in patients suffering from cystic fibrosis. This study integrated data from clinical trials and real-world experiences, encompassing more than 250,000 patient-years of treatment, alongside laboratory, animal, and genetic analyses. The investigation was initiated following reports of new or worsening psychiatric symptoms, such as depression and anxiety, in a small subset of patients undergoing these therapies.
The analysis reviewed data from 72 Phase II and Phase III clinical trials, revealing that the overall rate of neuropsychiatric events was 7.4 per 100 person-years for those on CFTR modulators, compared to 9.5 per 100 person-years for those receiving a placebo. Serious neuropsychiatric events and those resulting in treatment discontinuation were rare and occurred at comparable rates across both groups. The study included five different treatment regimens, including elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor.
Registry data indicated no significant changes in the rates of depression or anxiety diagnoses following the initiation of elexacaftor/tezacaftor/ivacaftor treatment. In a review of 12 studies assessing depression scores post-treatment, eight studies reported no changes, three indicated improvements, and one showed mixed results based on the assessment tools used. Similarly, among 11 studies evaluating anxiety, nine found no change while two reported improvements.
Laboratory tests showed no significant off-target binding at clinically relevant concentrations of the drugs. Behavioral studies conducted on rats did not reveal any measurable changes in behavior. Furthermore, genetic analysis involving around 1 million individuals found no correlation between CFTR variants and any of the 23 neuropsychiatric conditions examined.
While the findings from clinical trials and registries suggest a low risk of neuropsychiatric events, the lack of systematic collection of detailed neuropsychiatric assessments limits the ability to identify rare or subtle effects. Additionally, individuals with pre-existing mental health conditions may have been underrepresented in the trials. Thus, while population-level data is reassuring, there remains the potential for rare adverse effects in individual patients who may report symptoms after starting treatment.




